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Despite many advances in the management of hypertensive
chronic kidney disease (CKD) patients, both on and off
dialysis, there exist several gaps in our knowledge. Although
the modern techniques to measure blood pressure (BP)
indirectly have been available for a long time, among those
with CKD, how to best assess hypertension and the level to
which it should be lowered are mired in controversy. Other
controversial areas relate to a lack of a consensus definition
of hypertension among hemodialysis patients, uncertainty in
the definition and assessment of volume excess, and the lack
of adequately powered randomized trials to evaluate the
level to which BP can be lowered in those on dialysis. This
review discusses the limitations of the available evidence
base and suggests areas for future research. Suggestions
include evaluation of techniques to assess volume,
randomized trials to target different levels of BP among
hypertensive hemodialysis patients, evaluation of ambulatory
BP monitoring, and non-pharmacological means to lower BP
in CKD. It is hoped that among patients with CKD these data
will improve the dismal cardiovascular outcomes.
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Hypertension is both a cause and effect of chronic kidney
disease (CKD). There is little doubt about this bidirectional
and causal relationship, the evidence for which comes from
epidemiological, clinical, and research models. Although the
modern techniques to measure blood pressure (BP) were
described over a 100 years ago by Riva Rocci and Nikolai
Korotkoff, how to best assess hypertension and the level to
which it should be lowered among those with CKD is mired
in controversy. This controversy is especially vexing among
patients with end-stage renal disease on chronic hemodia-
lysis. In these patients, large volume shifts from before to
after dialysis cause wide BP variations. These variations make
the optimal timing and definition of hypertension proble-
matic. The gaps in our knowledge that need to be addressed
in patients with CKD and those on dialysis are discussed
further.
CKD PATIENTS NOT ON DIALYSIS
Joint National Commission-6 recommended lowering BP
to o125/75mmHg among those with 41 g proteinuria.
However, these recommendations were removed as they were
based on post hoc analyses. Among patients with CKD who
are not on dialysis, Joint National Commission-7 guidelines
recommend lowering BP to o130/80mmHg.1 However,
even these recommendations are based on largely observa-
tional data or post hoc analyses of randomized controlled trial
data. In fact, the three randomized controlled clinical trials
that targeted BP to two different levels among patients with
CKD have failed to confirm the superiority of one level over
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the other with respect to renal or cardiovascular outcomes.2–4
Each of these three clinical trials targeted BP measured in the
clinic. It is now becoming increasingly apparent that BP levels
assessed in the clinic do not agree well with the usual level of
BP; the usual level of BP is commonly assessed using 24-h
ambulatory BP monitoring.5 Using 24-h ambulatory BP
monitoring as the reference standard, a recent meta-analysis
revealed that B20% of patients with CKD have white coat
hypertension and about 5–10% have masked hypertension.6
Other studies using more liberal definitions of masked
hypertension have found a much higher prevalence of
masked hypertension. The classification of patients into
these two categories of masked hypertension and white coat
hypertension is of more than statistical importance. Patients
with white coat hypertension, whether assessed using
ambulatory BP or home BP recordings, have a prognosis
that is substantially better than those with sustained
hypertension.7 On the other hand, patients with masked
hypertension have a prognosis that is substantially worse than
those with persistent normotension.8 These data suggest that
the diagnosis and treatment of hypertension based on home
BP recordings would be superior to those based on clinical
recordings alone.9 In fact, both European and US guidelines
suggest home BP monitoring for all patients, including those
with CKD.10,11 Despite these recommendations, the precise
method of how to measure home BP, how frequently to
measure it, and how low to target the BP goal requires more
study. Accordingly, home measurements should be system-
atically tested in larger populations of patients with CKD.
Although many trials have demonstrated that manage-
ment of hypertension in the population without CKD with
home BP monitoring leads to better BP control, only two
such trials have been conducted in those with CKD.12,13
Accordingly, there is an urgent need to conduct such trials in
those with CKD to evaluate the risks and benefits of this
simple and effective therapy to treat hypertension. If trials
demonstrate that superior outcomes can be obtained with
home BP monitoring, it could transform the management of
patients with CKD.
It has long been recognized that the presence of even the
slightest kidney disease causes blunting of the usual nocturnal
decline in systolic BP with sleep.14,15 This phenomenon of
non-dipping among patients with CKD has been associated
with poor outcomes in some but not all studies.16–18 BP
patterns, besides the usual level of BP, may or may not
contain prognostic information.19 Determination of the
independent prognostic significance of BP patterns among
patients with CKD needs to be further studied.20 In
particular, it is unknown whether non-dipping is a mediator
or a marker of poor outcomes. This notion can only be tested
in randomized trials.
CKD is a state of accelerated vascular aging. Many studies
have used pulse pressure as a proxy of vascular age. These
studies have shown a strong and linear relationship between
pulse pressure and mortality among dialysis patients.
However, pulse pressure is not the best proxy of vascular
age. Vascular age is better reflected by increased arterial
stiffness; this can be easily measured by carotid to femoral
pulse wave velocity. There is an excellent relationship between
directly measured intra-aortic pulse wave velocity and
systolic interdialytic ambulatory BP.21 There is also ample
evidence to draw a direct relationship between pulse wave
velocity and adverse outcomes among dialysis patients.20
How the evaluation of arterial stiffness adds to the manage-
ment of hypertension among patients with CKD now needs
to be better defined. As arterial stiffness through the
measurement of pulse wave velocity and central BP can be
measured using the same equipment, it is possible to evaluate
the role of central BP and pulse wave velocity simultaneously.
END-STAGE RENAL DISEASE PATIENTS
Among patients on chronic dialysis, the clinical guidelines for
the level to which BP should be lowered are opinion based.
These opinions suggest lowering predialysis BP to o140/
90mmHg and postdialysis BP to o130/80mmHg.22 How-
ever, some data suggest that achieving these targets is
associated with increased episodes of intradialytic hypoten-
sion.23 In fact, collective evidence suggests that predialysis
and postdialysis BP measurements are poor estimates of
interdialytic ambulatory BP measurements.24 In contrast to
peridialytic BP measurements, BP measurements outside the
dialysis unit are associated with target organ damage and
prognosis.25–27 Furthermore, at least one randomized trial
has suggested that when BP is targeted using home BP rather
than pre- or postdialysis measurements, better ambulatory
BP control is achieved at 6 months.12 These data further
support the use of home BP monitoring in the management
of hypertension among hemodialysis patients.
A vexing problem especially among chronic hemodialysis
patients is that of assessment of volume and its relationship
with BP. The concept of dry weight has evolved over time and
its definition has changed. Although there is no consensus on
its definition, one such definition defines dry weight as the
lowest tolerated postdialysis weight achieved by a gradual
change in postdialysis weight at which there are minimal
signs or symptoms of either hypovolemia or hypervolemia.
Although clinical examination does not adequately detect
latent increase in dry weight, several technologies such as
relative plasma volume monitoring and body impedance
analysis are emerging that may help in assessing dry weight in
the future. There is a need to better evaluate these
technologies.
Among dialysis patients, volume overload, often subclini-
cal, is the primary cause of resistant hypertension. Sodium
restriction is a modifiable risk factor that can lead to better
BP control. However, dietary sodium restriction requires
lifestyle modifications that are difficult to implement, and
even harder to sustain over the long term. Newer options
may include resins that bind dietary sodium. Restricting
dialysate sodium is a simpler but underexplored strategy that
can reduce thirst, limit interdialytic weight gain, and assist in
the achievement of dry weight. However, larger studies with
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firm end points are needed. Achievement of dry weight can
improve interdialytic BP, reduce pulse pressure, and limit
hospitalizations. Accordingly, reduction of volume overload
with dietary and dialysate sodium restriction and periodic
probing of dry weight is believed to be good clinical
practice.28 Avoiding medication-directed control of BP may
enhance the opportunity to probe dry weight, facilitate
removal of volume, and limit the risk for pressure–volume
overload, which may be a significant concern leading to
myocardial remodeling in the hemodialysis patient. Probing
dry weight among patients with end-stage renal disease has
the potential to improve dismal cardiovascular outcomes.
The use of drugs to improve BP control among chronic
hemodialysis patients is even more debatable. Epidemiologi-
cal studies demonstrate that a lower BP and decline in BP
over months or years are associated with higher mortality in
dialysis patients. In contrast, randomized, controlled trials so
far available have a low power to establish the benefits of
antihypertensive therapy. A meta-analysis of five studies
among 1202 hemodialysis patients demonstrated the overall
benefit of antihypertensive therapy compared with the
control or placebo group. It found a combined hazard ratio
for cardiovascular events of 0.69 (95% confidence interval:
0.56–0.84).29 This meta-analysis suggests benefit but does
not establish the value of the antihypertensive drug among
hemodialysis patients. It remains unclear whether strategies to
control BP with dry weight or drugs have associated risks such
as increased episodes of intradialytic hypotension, subclinical
myocardial ischemia, access dysfunction, and an accelerated
demise of residual renal function. Thus, the risks and benefits
of these techniques on cardiovascular outcomes need to be
evaluated in adequately powered randomized trials.
In conclusion, despite many advances in the management
of patients with CKD, both on and off dialysis, there exist
several gaps in our knowledge. These relate to the definition
of hypertension, assessment of volume, and evaluation of
outcomes (see Figure 1).
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